Hi Lenochka,
I have been looking for some high quality research papers to see if they support what you are saying.
Enhancement of allo-responsiveness of human lymphocytes by acemannan (Carrisyn).
Womble D, Helderman JH.
Renal Immunology Laboratory, University of Texas Southwestern Medical Center, Dallas.
Healing powers have been imputed as being a feature of the gel from the aloe vera plant for centuries. The recent isolation of the active ingredient, acemannan, has made testing of this drug important. Since the drug appears to enhance monocyte function in other experiments, these studies were designed to test the capacity of acemannan to enhance immune response to alloantigen and to test whether the potential enhancement is a monocyte driven phenomenon. Acemannan did not enhance lymphocyte response to syngeneic antigens in the mixed lymphocyte culture (MLC) but importantly increased alloantigenic response in a dose-response fashion (2.6 x 10(-7) - 2.6 x 10(-9)M). This effect of acemannan was shown to be a specific response and to concur with concentrations of in vitro acemannan achievable in vivo. A separate series of mixing experiments demonstrated that acemannan incubation with monocytes permitted monocyte driven signals to enhance T-cell response to lectin. It is concluded that acemannan, the active ingredient of the aloe vera plant, is an important immunoenhancer in that it increases lymphocyte response to alloantigen. It is suggested that the mechanism involves enhancement of monocyte release of IL-I under the aegis of alloantigen. This mechanism may explain in part the recently observed capacity of acemannan to abrogate viral infections in animal and man.
Merely isolating an active ingredient proves nothing more than it should be looked at and some experiments done, you need big trials (N= lots of people) carried out in a quality scientific study, blinded, placebo controlled with random selection of participants, and even then it must be duplicated many times before you can be sure that you have removed all possible bias.
Here is another one.
TS | REGISTER | CUSTOMER SUPPORT | NIH PUBLIC ACCESS POLICY
lwwlogo banner
Home Search Current Issue Archive Publish Ahead of Print
April 2007, 16:2 > Effect of Aloe vera leaf pulp extract...
< Previous | Next >
ARTICLE LINKS:
Fulltext | PDF (468 K) | Request Permission
European Journal of Cancer Prevention:Volume 16(2)April 2007pp 151-157
Effect of Aloe vera leaf pulp extract on Ehrlich ascites tumours in mice
[Research papers: Other Cancers]
Akev, Nuriyea; Turkay, Gulhanb; Can, Aysea; Gurel, Aydncı; Yildiz, Fundac; Yardibi, Hasretb; Ekiz, Elif Erguld; Uzun, Hafizee
aDepartment of Biochemistry, Faculty of Pharmacy, Istanbul University, Beyazit
Departments of bBiochemistry
cPathology
dPhysiology, Veterinary Faculty, Istanbul University, Avcilar
eDepartment of Biochemistry, Cerrahpasa Faculty of Medicine, Istanbul University, Cerrahpasa, Istanbul, Turkey
Correspondence to Mrs Nuriye Akev, Department of Biochemistry, Faculty of Pharmacy, Istanbul University, 34116 Beyazit, Istanbul, Turkey
Tel: +90 212 440 02 74; fax: +90 212 440 02 52; e-mail: nakev@istanbul.edu.tr
Sponsorship: This work was supported by Istanbul University Research Fund (Project Number: 37/11092002).
Received 30 September 2005 Accepted 11 January 2006
Abstract
Among the various known therapeutic effects of Aloe vera (L.) Burm. fil., a few recent studies have shown that preparations of the plant leaves can prevent or regress the growth of certain tumours. In this study, undertaken with A. vera leaf pulp extract against Ehrlich ascites tumours in mice, the animals were separated into five groups: I - healthy control, II - tumour control, III - experiment 1 (extract given before tumour inoculation), IV - experiment 2 (extract given with tumour inoculation) and V - experiment 3 (extract given after tumour inoculation). Ehrlich ascites tumours (0.33 ml) were injected subcutaneously into groups II-V. Aloe extract was injected at 55 mg protein/kg, twice a week for 21 days. Tumour size, thymus and spleen weights were measured, as well as leucocyte count, tumour necrosis factor-α and sialic acid as tumour markers. The best inhibitory effect on tumour growth was obtained with the extract given prophylactically before tumour implantation (experiment 1), although Aloe extract also regressed tumour sizes when given simultaneously with (experiment 2), or therapeutically after (experiment 3), tumour implantation. Accordingly, serum sialic acid and tumour necrosis factor-α levels, chosen as tumour markers, which were raised in the tumour control group, were significantly decreased by the prophylactic administration of the extract. The increase in leucocyte count seen in experiment 1 and 2 groups, along with lymphoid hyperplasia observed in spleen and thymus necroscopy, lead us to think that the tumour preventive effect of Aloe could be due to its immunomodulatory activity. According to our results, A. vera could be proposed as a prophylactic for cancer prevention.
And another one.
NCBI
PubMed A service of the U.S. National Library of Medicine
and the National Institutes of Health
My NCBI My NCBI help
[Sign In] [Register]
* All Databases
* PubMed
* Nucleotide
* Protein
* Genome
* Structure
* OMIM
* PMC
* Journals
* Books
SearchDatabase nameforSearch term Go Clear
* Advanced Search
* Limits
* Preview/Index
* History
* Clipboard
* Details
Display Show
All: 1 Review: 1
Click to change filter selection through MyNCBI.
1: Br J Gen Pract. 1999 Oct;49(447):823-8.Click here to read Click here to read Links
Aloe vera: a systematic review of its clinical effectiveness.
Vogler BK, Ernst E.
Department of Complementary Medicine, School of Postgraduate Medicine and Health Sciences, University of Exeter.
BACKGROUND: The use of aloe vera is being promoted for a large variety of conditions. Often general practitioners seem to know less than their patients about its alleged benefits. AIM: To define the clinical effectiveness of aloe vera, a popular herbal remedy in the United Kingdom. METHOD: Four independent literature searches were conducted in MEDLINE, EMBASE, Biosis, and the Cochrane Library. Only controlled clinical trials (on any indication) were included. There were no restrictions on the language of publication. All trials were read by both authors and data were extracted in a standardized, pre-defined manner. RESULTS: Ten studies were located. They suggest that oral administration of aloe vera might be a useful adjunct for lowering blood glucose in diabetic patients as well as for reducing blood lipid levels in patients with hyperlipidaemia. Topical application of aloe vera is not an effective preventative for radiation-induced injuries. It might be effective for genital herpes and psoriasis. Whether it promotes wound healing is unclear. There are major caveats associated with all of these statements. CONCLUSION: Even though there are some promising results, clinical effectiveness of oral or topical aloe vera is not sufficiently defined at present.
PMID: 10885091 [PubMed - indexed for MEDLINE]
As you can clearly see from this there is still a lot of work to be done before you could safely say Aloe Vera could cure/prevent anything.
Cheers